Trial Profile

Phase 1 study to evaluate the safety, tolerability and pharmacokinetics of oral WCK 2349 (200 mg or 400 mg or 600mg or 800mg or 1000 mg or 1500mg) on single dose administration in adult healthy male human volunteers under fasting conditions.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alalevonadifloxacin (Primary)
Indications Bacterial infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
Focus Adverse reactions; Pharmacokinetics

21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
21 Nov 2012 Planned number of patients (84) added as reported by Clinical Trials Registry - India record.
08 Feb 2010 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com